Solid Biosciences Inc（SLDB）财务数据SLDBSolid Biosciences Inc

Evaluating the bottom line, Solid Biosciences Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -65.50%, provide a clear picture of how effectively SLDB converts its operational activities into shareholder value.

In the context of the broader market, SLDB competes directly with industry leaders such as ATTO and DSGN. With a market capitalization of $757.01M, it holds a leading position in the sector. When comparing efficiency, SLDB's gross margin of N/A stands against ATTO's 100.00% and DSGN's N/A. Such benchmarking helps identify whether Solid Biosciences Inc is trading at a premium or discount relative to its financial performance.

Solid Biosciences has been experiencing significant net losses, with projected net income reaching -$56.7 million in Q1 2026. However, it maintains a strong current ratio of 13.82, indicating good short-term financial health.